TY-9591

Phase 3Small molecule

TTYK Medicines, Inc

TY-9591 is one of 82 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

GrowthActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

GrowthPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

TY-9591

TTYK Medicines, Inc

Phase 3

2 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Remeron

OOrganon and Co

Preclinical

1 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

1 9

REGN2810

Regeneron

Preclinical

1 10

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT05382728

Phase 2Recruiting

Brain Metastases

NCT05948813

Q4 2028

Phase 2Not yet recruiting

Growth

NCT06672068

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

Completed·TTYK Medicines, Inc·Phase 1·NCT04204473·105 enrolled

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Recruiting·TTYK Medicines, Inc·Phase 3·NCT05382728·680 enrolled

Growth1 trial

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Not yet recruiting·TTYK Medicines, Inc·Phase 2·NCT06672068·60 enrolled

Tics1 trial

A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Completed·TTYK Medicines, Inc·Phase 1·NCT04798638·16 enrolled

Brain Metastases1 trial

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Recruiting·TTYK Medicines, Inc·Phase 2·NCT05948813·420 enrolled

Lung Cancer1 trial

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Completed·TTYK Medicines, Inc·Phase 2·NCT05146219·29 enrolled

1 more indication

Unspecified1 trial

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Completed·TTYK Medicines, Inc·Phase 1·NCT05871905·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for TY-9591. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TY-9591 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TY-9591. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TYK Medicines, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTYK Medicines, Inc

TY-9591

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Growth1 trial

Tics1 trial

Brain Metastases1 trial

Lung Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News